卵巢癌：KOL 見解

本報告匯集了 KOL 對卵巢癌藥物最新趨勢和未來前景的見解。特別是卵巢癌治療的演變，包括 Lynparza 等 PARP 抑制劑的持續重要性、來自抗體藥物偶聯物（ADC）的新興競爭，以及 sarparib 和下一代 PARPis 等新型治療的前景。也強調了 Hlahere（ImmonoGen）在鉑抗藥性環境中的有希望的結果以及對 Enhertu（AstraZeneca）的謹慎樂觀態度。然而，重大挑戰仍然存在，特別是與免疫療法和某些實驗性治療的聯合療法。

本報告調查的主要品牌：

接受調查的公司：

Novartis、Lilly、Roche、GSK、AstraZeneca、Pfizer、Merck、Merck & Co.、Bristol Myers Squibb、Genentech、Daiichi Sankyo、ImmunoGen、Menarini、Johnson & Johnson Innovative Medicine、Merck Group、Corcept Therapeutics、Ono Pharmaceutical、Alkermes、Zymeworks、OncoQuest、Gradalis、Verastem Oncology、Sutro Biopharma、Genelux、pharma&、Antengene、Artios Pharma、Karyopharm Therapeutics、Klus Pharma、Zentalis Pharmaceuticals。

本報告回答的關鍵問題：

• 目前卵巢癌的基本治療方法是什麼？它的優點和缺點是什麼？
• 醫學界對 PARP 抑制劑（Lynparza、Rubraca、Zejula 等）的功效、耐受性和易用性有何看法？
• 哪些最近或進行的臨床試驗可能對處方趨勢產生重大影響？此外，這些結果對未來卵巢癌的治療有何影響？
• 新的標靶治療必須證明什麼才能成為特定患者群體的首選治療方法？另外，是否有可能滿足這樣的標準？
• 哪些在研產品最有前途？對目前的市場參與者會產生什麼影響？

目錄

執行摘要

目前與未來的治療演算法

研究目的

產品已上市

• PARPis
  • 有關PARPis (Lynparza, Rubraca, Zejula) 的見解
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Rubraca (rucaparib; Pharma& Schweiz)
  • Zejula (niraparib; GSK)
• ADC/微管蛋白/DNA 拓樸異構酶 I 抑制劑
  • 關於 ADC/微管蛋白/DNA 拓樸異構酶 I 抑制劑的見解
  • Elahere (mirvetuximab soravtansine; ImmunoGen)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)

在研產品

• 免疫檢查點抑制劑（ICIs）
  • ICI 級見解
  • Bavencio (avelumab; Merck Group)
  • Imfinzi (durvalumab; AstraZeneca)
  • Jemperli (dostarlimab; GSK)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono)
  • Tecentriq (atezolizumab; Roche)
  • 免疫興奮劑
  • 對免疫增強劑的見解
  • Oregovomab (anti-idiotype mAb; OncoQuest)
• 治療性疫苗
  • 對治療性疫苗的見解
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis)
• 下一代 ADC
  • 關於下一代 ADC 的見解
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma)
  • R-DXd (raludotatug deruxtecan; Daiichi Sankyo/Merck & Co.)
• 其他後期治療
  • 關於 MAP/RAF/FA 激酶抑制劑的見解
  • VS 6766/VS 6063 (avutometinib/defactinib; Verastem Oncology)
• 糖皮質激素受體拮抗劑
  • CORT-125134 (relacorilant; Corcept Therapeutics)
• 中期和早期階段的模式
  • Next-generation ADCs and other MOAs
  • ART6043 (Artios Pharma)
  • AZD-5305 (saruparib; AstraZeneca)
  • AZD 6738 (ceralasertib; AstraZeneca)
  • AZD 8205 (AstraZeneca)
  • IMGN 151 (ImmunoGen)
  • KP-2638/ZN-c3 (azenosertib; Zentalis Pharmaceuticals)
  • MK-2870 (sacituzumab tirumotecan; Klus Pharma/Merck & Co)
  • Nexpovio/Xpovio (selinexor; Antengene/Karyopharm Therapeutics/Menarini)
  • Rina-S (rinatabart sesutecan; ProfoundBio)
  • Verzenio/Verzenios (abemaciclib; Eli Lilly and Company)
  • ZW 191 (Zymeworks)

    附錄

    • KOL 詳細信息
      • 美國的KOL
      • 歐洲 KOL

    新聞

KOLs critically assess the evolving landscape of ovarian cancer treatment, including the sustained importance of PARP inhibitors like Lynparza, emerging competition from antibody-drug conjugates (ADCs), and the future potential of novel therapies such as saruparib and next-generation PARPis. Explore the promising outcomes of ImmunoGen's Elahere in platinum-resistant settings and the cautious optimism surrounding AstraZeneca's Enhertu, among others. However, significant challenges remain, particularly for immunotherapy combinations and certain experimental treatments.

Key brands covered in this report:

Companies:

Novartis, Lilly, Roche, GSK, AstraZeneca, Pfizer, Merck, Merck & Co., Bristol Myers Squibb, Genentech, Daiichi Sankyo, ImmunoGen, Menarini, Johnson & Johnson Innovative Medicine, Merck Group, Corcept Therapeutics, Ono Pharmaceutical, Alkermes, Zymeworks, OncoQuest, Gradalis, Verastem Oncology, Sutro Biopharma, Genelux, pharma&, Antengene, Artios Pharma, Karyopharm Therapeutics, Klus Pharma, Zentalis Pharmaceuticals.

Key questions answered:

• What are the current backbone treatments for ovarian cancer, and what are their pros and cons?
• How does the medical community view PARP inhibitors like Lynparza, Rubraca, and Zejula in terms of efficacy, tolerability, and ease of use, and how might their usage change?
• Which recent or ongoing clinical trials could significantly impact prescribing trends, and what will their results mean for the future of ovarian cancer treatment?
• What must emerging targeted therapies demonstrate to become the preferred treatments for specific patient segments, and are they likely to meet these criteria?
• Which pipeline products show the most promise, and how will they affect current market players?

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed products

• PARPis
  • Insights for the PARPis (Lynparza, Rubraca, Zejula)
  • Lynparza (olaparib; AstraZeneca/Merck & Co.)
  • Rubraca (rucaparib; Pharma& Schweiz)
  • Zejula (niraparib; GSK)
• ADC/tubulin/DNA topoisomerase I inhibitors
  • Insights for the ADC/tubulin/DNA topoisomerase I inhibitors
  • Elahere (mirvetuximab soravtansine; ImmunoGen)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)

Pipeline products

• Immune checkpoint inhibitors (ICI)
  • Insights for the ICI class
  • Bavencio (avelumab; Merck Group)
  • Imfinzi (durvalumab; AstraZeneca)
  • Jemperli (dostarlimab; GSK)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo/Yervoy (nivolumab/ipilimumab; BMS/Ono)
  • Tecentriq (atezolizumab; Roche)
  • Immunostimulants
  • Insights for the immunostimulants
  • Oregovomab (anti-idiotype mAb; OncoQuest)
• Therapeutic vaccines
  • Insights for the therapeutic vaccines
  • Olvi-Vec (olvimulogene nanivacirepvec; Genelux Corporation)
  • Vigil (Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine; Gradalis)
• Next-generation ADCs
  • Insights for the next-generation ADCs
  • STRO-002 (luveltamab tazevibulin; Sutro Biopharma)
  • R-DXd (raludotatug deruxtecan; Daiichi Sankyo/Merck & Co.)
• Other late-stage modalities
  • Insights on MAP/RAF/FA kinase inhibitors
  • VS 6766/VS 6063 (avutometinib/defactinib; Verastem Oncology)
• Glucocorticoid receptor antagonists
  • CORT-125134 (relacorilant; Corcept Therapeutics)
• Mid and early-stage modalities
  • Next-generation ADCs and other MOAs
  • ART6043 (Artios Pharma)
  • AZD-5305 (saruparib; AstraZeneca)
  • AZD 6738 (ceralasertib; AstraZeneca)
  • AZD 8205 (AstraZeneca)
  • IMGN 151 (ImmunoGen)
  • KP-2638/ZN-c3 (azenosertib; Zentalis Pharmaceuticals)
  • MK-2870 (sacituzumab tirumotecan; Klus Pharma/Merck & Co)
  • Nexpovio/Xpovio (selinexor; Antengene/Karyopharm Therapeutics/Menarini)
  • Rina-S (rinatabart sesutecan; ProfoundBio)
  • Verzenio/Verzenios (abemaciclib; Eli Lilly and Company)
  • ZW 191 (Zymeworks)

Appendix

• KOL details
  • KOLs from the US
  • KOLs from Europe

News